Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) insider Lonnel Coats bought 30,000 shares of the company’s stock in a transaction on Friday, September 15th. The stock was bought at an average price of $12.54 per share, for a total transaction of $376,200.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of Lexicon Pharmaceuticals, Inc. (LXRX) opened at 12.37 on Monday. Lexicon Pharmaceuticals, Inc. has a 12-month low of $11.80 and a 12-month high of $19.62. The company’s 50-day moving average is $14.62 and its 200-day moving average is $15.32. The company’s market cap is $1.31 billion.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.12. Lexicon Pharmaceuticals had a negative net margin of 170.63% and a negative return on equity of 94.87%. The business had revenue of $12.00 million for the quarter, compared to the consensus estimate of $18.34 million. During the same quarter in the previous year, the firm earned ($0.37) earnings per share. The company’s revenue for the quarter was down 40.3% on a year-over-year basis. Equities research analysts predict that Lexicon Pharmaceuticals, Inc. will post ($1.45) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This article was originally published by Daily Political and is the property of of Daily Political. If you are reading this article on another website, it was stolen and republished in violation of international copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/18/lonnel-coats-buys-30000-shares-of-lexicon-pharmaceuticals-inc-lxrx-stock.html.

A number of research analysts have weighed in on LXRX shares. Zacks Investment Research upgraded shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 18th. Wedbush reissued an “ourperform” rating and issued a $39.00 price target on shares of Lexicon Pharmaceuticals in a research report on Monday, August 7th. BidaskClub lowered shares of Lexicon Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, August 2nd. Cowen and Company reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Tuesday, August 1st. Finally, ValuEngine raised shares of Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $27.00.

Institutional investors have recently added to or reduced their stakes in the company. State of Wisconsin Investment Board bought a new stake in shares of Lexicon Pharmaceuticals during the second quarter valued at approximately $510,000. Highbridge Capital Management LLC bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $7,813,000. Pictet Asset Management Ltd. raised its position in shares of Lexicon Pharmaceuticals by 10.4% during the second quarter. Pictet Asset Management Ltd. now owns 67,950 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 6,400 shares during the last quarter. Sector Gamma AS bought a new stake in shares of Lexicon Pharmaceuticals during the first quarter valued at approximately $4,765,000. Finally, First Mercantile Trust Co. raised its position in shares of Lexicon Pharmaceuticals by 11.2% during the second quarter. First Mercantile Trust Co. now owns 12,212 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 1,227 shares during the last quarter.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of breakthrough treatments for human disease. Its drug programs include XERMELO (telotristat ethyl), sotagliflozin, LX2761 and LX9211. It also has a number of additional compounds into various stages of clinical and preclinical development.

Receive News & Ratings for Lexicon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.